OpenAI Pushes Deeper Into Drug Discovery With GPT-Rosalind Upgrade

https://img-cdn.publive.online/fit-in/1200x675/ciol/media/media_files/2026/06/04/gpt-rosalind-upgrade-2026-06-04-15-25-51.png

OpenAI is expanding its ambitions in life sciences with a major update to GPT-Rosalind, its specialised AI platform designed for scientific research, drug discovery, and biological analysis.

The latest release combines GPT-5.5's coding and tool-use capabilities with stronger performance in medicinal chemistry, genomics, quantitative biology, and laboratory research workflows. More importantly, it marks another step in OpenAI's effort to move beyond general-purpose AI and build systems tailored for highly specialised scientific domains.

The updated GPT-Rosalind is now available in research preview for eligible organisations through OpenAI's trusted-access deployment framework.

From General AI To Life Sciences

While most AI discussions continue to focus on productivity tools and chat-based assistants, OpenAI is quietly building a dedicated life sciences stack through its Rosalind initiative.

The latest update reflects a broader shift in strategy. Rather than positioning AI as a tool that simply answers scientific questions, OpenAI wants GPT-Rosalind to participate in research workflows...

Copyright of this story solely belongs to ciol.com. To see the full text click HERE

Read more